The Latest Breaking News from Albert Bourla

Analysts say gold is benefited from safe-haven demand amid persistent geopolitical tensions, expectations of monetary policy easing, and mounting uncertainty surrounding the US presidential election.

Pfizer is getting back on track—but an even more potent prescription for success could be in the cards for the pharmaceutical giant under.

Starboard took aim at Pfizer in another blow Tuesday, saying the company has failed to deliver on what it called the "best pipeline" ever.

This dividend stock is now on the radar of activist investors, with Starboard eyeing a possible management shakeup.

Pfizer stock skidded Thursday after former executives Ian Read and Frank D'Amelio sided with the drugmaker over activist investor Starboard.

The drugmaker has shed nearly $180 billion in market cap after struggling to chart a new course as the COVID-19 pandemic waned.

Pfizer's CEO Albert Bourla is trying to reposition the global pharmaceutical giant for a post-pandemic world

A Belgian court on Friday heard a lawsuit accusing European Commission chief Ursula von der Leyen of secretly negotiating Covid vaccine purchases via text message and arguing she should be barred from a second term.

While the S&P 500 Index's dividend yield is just about half of its long-term averages, Ford and Pfizer are two dividend-paying stocks that offer healthy yields. Plus, their cheap valuations mean that there is a reasonable probability of upside over the next couple of years.

Pfizer issued a disappointing 2024 forecast Wednesday, denting shares as the company navigates a profound plunge in sales tied to the Covid-19 pandemic.

Pfizer announced Tuesday that it expects to complete this week its $43 billion acquisition of cancer-focused biotech company Seagen after clearing key regulatory hurdles.